Time-motion analysis of 6 cystic fibrosis mutation detection systems

Clinical Chemistry

Volumn 51, Issue 7, 2005, Pages 1116-1122

  Krafft, Amy E ^a   Lichy, Jack H ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN;

ARTICLE; ASSAY; CONTROLLED STUDY; CYSTIC FIBROSIS; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MANUAL LABOR; MEDICAL INSTRUMENTATION; MEDICAL TECHNOLOGIST; METHODOLOGY; MICROARRAY ANALYSIS; MOTION ANALYSIS SYSTEM; MUTATIONAL ANALYSIS; SLOT BLOT HYBRIDIZATION; TIME PERCEPTION; COMPARATIVE STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; GENETICS; MUTATION; TASK PERFORMANCE;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MUTATION; TIME AND MOTION STUDIES;

EID: 23444440644     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.047423     Document Type: Article

References (18)

1. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med 2002;4:90-4.
2. The Hospital for Sick Children, http://www.genet.sickkids.on.ca/cftr/ (accessed February 22, 2005).
3. Heim RA, Sugarman EA, Allitto BA. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genet Med 2001;3:168-76.
4. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387-91.
5. Sugarman EA, Rohlfs EM, Silverman LM, Allitto BA. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. Genet Med 2004;6:392-9.
6. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-54.
7. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, et al. Standards and guidelines for CFTR mutation testing. Genet Med 2002;4:379-91.
8. Barnes RM. Motion and time study design and measurement of work, 7th ed. New York: John Wiley & Sons, 1980:689pp.
9. Meyers FE, Stewart JR. Motion and time study for lean manufacturing, 3rd ed. Upper Saddle River, NJ: Prentice Hall, 2002:370pp.
10. Krafft A, Przybocki J, Dement J, Campbell S, Johnson D, Lichy JH. Time-motion analysis of six cystic fibrosis mutation detection systems [Abstract]. J Mol Diagn 2004;6:408.
11. Lichy JH, Hu F, Przybocki J, Bijwaard KE, Dement J. An approach to positive controls for cystic fibrosis mutation detection [Abstract]. J Mol Diagn 2002;4:255.
12. Brinson EC, Adriano T, Bloch W, Brown CL, Chang CC, Chen J, et al. Introduction to PCR/OLA/SCS, a multiplex DNA test, and its application to cystic fibrosis. Genet Test 1997;1:61-8.
13. Eggerding FA, Iovannisci DM, Brinson E, Grossman P, Winn-Deen ES. Fluorescence-based oligonucleotide ligation assay for analysis of cystic fibrosis transmembrane conductance regulator gene mutations. Hum Mutat 1995;5:153-65.
14. Eggerding FA. A one-step coupled amplification and oligonucleotide ligation procedure for multiplex genetic typing. PCR Methods Appl 1995;4:337-45.
15. Gold B. Origin and utility of the reverse dot-blot [Review]. Expert Rev Mol Diagn 2003;3:143-52.
16. McDade R. A universal laboratory platform for the new millennium. Am Lab 2001;June:26-31.
17. Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 1999;4:353-64.
18. Amos J, French C, Gao D-Q, Ponek V, Thwe M, Kobler D, et al. Validation and implementation of a CF70 assay for enhanced detection of carriers [Abstract]. J Mol Diagn 2004;6:408.